David Cameron
Edinburgh Cancer Research · 876 works · 60,888 citations · h-index 99
Top works
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
- The benefits and harms of breast cancer screening: an independent review
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- Identification of molecular apocrine breast tumours by microarray analysis
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
- EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
- Triple-negative breast cancer: disease entity or title of convenience?